.png?width=1800&height=600&name=MicrosoftTeams-image%20(82).png)
2 min read
Geneva, Switzerland, 3 November 2016 – Selexis SA, a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1)…
2 min read
Geneva, Switzerland, 25 October 2016 – Selexis SA, a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1)…
2 min read
Organizations to Jointly Develop High Performance Research Cell Banks to Expedite the Manufacturing of Engineered HIV Envelope Proteins
1 min read
Geneva, Switzerland, 7 September 2016 – Selexis SA, a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1)…
2 min read
Geneva, Switzerland, and Singapore, 27 July 2016 – Selexis SA, a pioneering life sciences company and a global leader in mammalian…
2 min read
Turgut Ilaclari A.S. and Selexis SA Sign Service and Commercial Agreements to Progress Development of Biosimilar Products
2 min read
Geneva, Switzerland, 29 June 2016 – Selexis SA, a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell…
1 min read
Geneva, Switzerland, 21 June 2016 – Selexis SA, a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell…
1 min read
Geneva, Switzerland, 2 June 2016 – Selexis SA, a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell…
1 min read
Technology Addresses Secretion Bottlenecks in Recombinant Protein Expression
